Raphaël Porcher

Blockchain protocols in clinical trials: Transparency and traceability of consent

R. Porcher, P. Ravaud, M. Benchoufi, 2017, F1000Research.

Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials

B. Bonnotte, E. Daugas, F. Maurier, 2023, Annals of the Rheumatic Diseases.

Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial

G. Baron, P. Tharaux, C. Cazanave, 2023, BMJ medicine.

Efficacy and safety of convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized clinical trial

X. de Lamballerie, G. Baron, X. Mariette, 2022, medRxiv.

Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015

J. Jacot, R. Porcher, P. Ravaud, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients

L. Savale, H. Péré, P. Bastard, 2023, Frontiers in Immunology.

A Meta-analysis of Patellar Replacement in Total Knee Arthroplasty

R. Porcher, D. Biau, P. Ravaud, 2005, Clinical orthopaedics and related research.